Education
About Us
Working with TipRanks
Follow Us
Regeneron (REGN)
NASDAQ:REGN
REGN Stock Chart & Stats
$737.00
$9.02(1.24%)
At close: 4:00 PM EST
$737.00
$9.02(1.24%)
Day’s Range― - ―
52-Week Range$476.49 - $800.99
Previous CloseN/A
Volume208.99K
Average Volume (3M)1.05M
Market Cap
$73.86B
Enterprise Value$54.53B
Total Cash (Recent Filing)$8.44B
Total Debt (Recent Filing)$2.71B
Price to Earnings (P/E)17.4
Beta0.77
Next Earnings
Jan 30, 2026EPS Estimate
10.61Last Dividend Ex-Date
Nov 20, 2025Dividend Yield0.48%
Share Statistics
EPS (TTM)11.83
Shares Outstanding103,282,320
10 Day Avg. Volume1,034,925
30 Day Avg. Volume1,049,661
Financial Highlights & Ratios
PEG Ratio1.68
Price to Book (P/B)2.62
Price to Sales (P/S)5.41
P/FCF Ratio20.97
Enterprise Value/Market Cap0.74
Enterprise Value/Revenue3.83
Enterprise Value/Gross Profit4.48
Enterprise Value/Ebitda9.55
Forecast
1Y Price Target
$742.00Price Target Upside0.68% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering22
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Financial PerformanceA huge 23% bottom-line beat driven by higher revenue and favorable cost controls.
Product GrowthStrong Dupixent growth continues, with worldwide sales of $4.86B, up 12% over 2Q25, a nearly $20B annual run rate.
Regulatory ApprovalsApproval for Eylea HD RVO indication and Q4W dosing reads as a clear positive for REGN shares as the company executes following a series of clinical and regulatory setbacks.
Bears Say
Market Exposure RisksOne ongoing holdback is REGN’s high relative Medicare Part B exposure which could create an issue if a MFN framework is pursued.
Product Adherence IssuesInjectable formulation may be a disadvantage for adherence.
Regulatory ChallengesStrong uptake may still be somewhat hindered by the lack of approval of the pre-filled-syringe (PFS).
Regeneron News
REGN FAQ
What was Regeneron’s price range in the past 12 months?
Regeneron lowest stock price was $476.49 and its highest was $800.99 in the past 12 months.
What is Regeneron’s market cap?
Regeneron’s market cap is $73.86B.
When is Regeneron’s upcoming earnings report date?
Regeneron’s upcoming earnings report date is Jan 30, 2026 which is in 70 days.
How were Regeneron’s earnings last quarter?
Regeneron released its earnings results on Oct 28, 2025. The company reported $11.83 earnings per share for the quarter, beating the consensus estimate of $9.655 by $2.175.
Is Regeneron overvalued?
According to Wall Street analysts Regeneron’s price is currently Undervalued.
Does Regeneron pay dividends?
Regeneron pays a Quarterly dividend of $0.88 which represents an annual dividend yield of 0.48%. See more information on Regeneron dividends here
What is Regeneron’s EPS estimate?
Regeneron’s EPS estimate is 10.61.
How many shares outstanding does Regeneron have?
Regeneron has 103,282,320 shares outstanding.
What happened to Regeneron’s price movement after its last earnings report?
Regeneron reported an EPS of $11.83 in its last earnings report, beating expectations of $9.655. Following the earnings report the stock price went up 11.817%.
Which hedge fund is a major shareholder of Regeneron?
Currently, no hedge funds are holding shares in REGN
Regeneron Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$742.00 (0.68% Upside)
$742.00 (0.68% Upside)
Blogger Sentiment
Bullish
REGN Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 856.3K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $4.5M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Negative
Last 7 Days ▲ 0.1%
Last 30 Days ▼ 1.0%
Last 30 Days ▼ 1.0%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-5.21%
12-Months-Change
Fundamentals
Return on Equity
15.19%
Trailing 12-Months
Asset Growth
7.28%
Trailing 12-Months
Company Description
Regeneron
Regeneron Pharmaceuticals, Inc. is a leading biotechnology company based in the United States that focuses on the discovery, development, and commercialization of innovative medicines for the treatment of serious diseases. The company operates primarily in the biopharmaceutical sector, with a strong emphasis on therapeutic areas such as ophthalmology, immunology, oncology, and infectious diseases. Regeneron's core products include EYLEA, a treatment for eye diseases, and Dupixent, a medication for allergic and inflammatory conditions, among others. The company's commitment to research and development has established it as a key player in the biotech industry, driving advancements in targeted therapies and genetic medicine.
REGN Company Deck
REGN Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
Regeneron demonstrated strong sales growth in key products like Dupixent and Libtayo, along with significant R&D pipeline progress. However, challenges such as affordability issues for EYLEA and FDA-related setbacks tempered some positive outcomes. Overall, the company shows a robust financial position and commitment to innovation, but faces operational hurdles that need addressing.View all REGN earnings summariesREGN Revenue Breakdown
53.72% Net product sales
42.65% Collaboration revenue
3.63% Other
REGN Stock 12 Month Forecast
Average Price Target
$742.00
▲(0.68% Upside)
Technical Analysis
Ownership Overview
0.27% Insiders
26.13% Mutual Funds
16.89% Other Institutional Investors
29.57% Public Companies and Individual Investors